VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2024 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary,...
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
February 29, 2024 08:00 ET
|
VYNE Therapeutics Inc.
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional...
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
February 27, 2024 08:00 ET
|
VYNE Therapeutics Inc.
Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq:...
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 21, 2024 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative,...
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
January 10, 2024 08:00 ET
|
VYNE Therapeutics Inc.
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase...
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
January 03, 2024 08:00 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 07:45 ET
|
VYNE Therapeutics Inc.
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for...
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
November 07, 2023 08:00 ET
|
VYNE Therapeutics Inc.
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment...
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
November 01, 2023 16:15 ET
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
October 30, 2023 07:20 ET
|
VYNE Therapeutics Inc.
Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion...